Skip to main
CLBT

CLBT Stock Forecast & Price Target

CLBT Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cellebrite DI is poised for success as they continue to offer innovative solutions that meet the increasing demand for digital investigative and intelligence tools. With a strong presence in multiple regions and a diverse customer base, the company has shown consistent revenue growth and has a solid reputation in the industry. Strong partnerships and a well-performing stock also indicate a positive outlook for the company's future growth and success.

Bears say

Cellebrite DI is facing multiple risks that could negatively impact its growth, including dependence on law enforcement and government agencies for revenue, competition risks from other tech companies, and potential technological risks from smartphone manufacturers improving their security features. Additionally, the company's high valuation and exposure to government budget cycles may make it vulnerable to market corrections. Despite the company's strong customer base and growth potential, these risks contribute to a negative outlook for Cellebrite DI's stock.

CLBT has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cellebrite DI Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cellebrite DI Ltd (CLBT) Forecast

Analysts have given CLBT a Strong Buy based on their latest research and market trends.

According to 5 analysts, CLBT has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cellebrite DI Ltd (CLBT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.